Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease

BACKGROUND: Donepezil (23 mg/day) is approved by the US Food and Drug Administration for the treatment of patients with moderate to severe Alzheimer’s disease (AD). Approval was based on results from a 24-week, randomized, double-blind study of patients who were stable on donepezil 10 mg/day and ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Tariot, Pierre, Salloway, Steven, Yardley, Jane, Mackell, Joan, Moline, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493328/
https://www.ncbi.nlm.nih.gov/pubmed/22681723
http://dx.doi.org/10.1186/1756-0500-5-283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493328/
https://www.ncbi.nlm.nih.gov/pubmed/22681723
http://dx.doi.org/10.1186/1756-0500-5-283

Ejemplares similares